284 related articles for article (PubMed ID: 25542681)
1. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
3. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: Solid state characterization, in-vivo in-situ evaluation.
Teja A; Musmade PB; Khade AB; Dengale SJ
Eur J Pharm Sci; 2015 Oct; 78():234-44. PubMed ID: 26253355
[TBL] [Abstract][Full Text] [Related]
5. Solid self-microemulsifying drug delivery system of ritonavir.
Deshmukh A; Kulkarni S
Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Miller DA; Keen JM; Brough C; Ellenberger DJ; Cisneros M; Williams RO; McGinity JW
J Pharm Pharmacol; 2016 May; 68(5):678-91. PubMed ID: 26454138
[TBL] [Abstract][Full Text] [Related]
7. PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.
Rodríguez-Spong B; Acciacca A; Fleisher D; Rodríguez-Hornedo N
Mol Pharm; 2008; 5(6):956-67. PubMed ID: 19434919
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
9. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
10. Physical Stabilization of Pharmaceutical Glasses Based on Hydrogen Bond Reorganization under Sub-T
Tominaka S; Kawakami K; Fukushima M; Miyazaki A
Mol Pharm; 2017 Jan; 14(1):264-273. PubMed ID: 28043129
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions.
Dhore PW; Dave VS; Saoji SD; Bobde YS; Mack C; Raut NA
Pharm Dev Technol; 2017 Feb; 22(1):90-102. PubMed ID: 27291246
[TBL] [Abstract][Full Text] [Related]
12. Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability.
Guo S; Pham K; Li D; Penzak SR; Dong X
Int J Nanomedicine; 2016; 11():1451-60. PubMed ID: 27103803
[TBL] [Abstract][Full Text] [Related]
13. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.
Zhou D; Grant DJ; Zhang GG; Law D; Schmitt EA
J Pharm Sci; 2007 Jan; 96(1):71-83. PubMed ID: 17031846
[TBL] [Abstract][Full Text] [Related]
14. A Comparative Study of the Pharmaceutical Properties between Amorphous Drugs Loaded-Mesoporous Silica and Pure Amorphous Drugs Prepared by Solvent Evaporation.
Budiman A; Aulifa DL
Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745649
[TBL] [Abstract][Full Text] [Related]
15. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir.
Sinha S; Ali M; Baboota S; Ahuja A; Kumar A; Ali J
AAPS PharmSciTech; 2010 Jun; 11(2):518-27. PubMed ID: 20238187
[TBL] [Abstract][Full Text] [Related]
16. QbD based development of proliposome of lopinavir for improved oral bioavailability.
Patel GM; Shelat PK; Lalwani AN
Eur J Pharm Sci; 2017 Oct; 108():50-61. PubMed ID: 27586019
[TBL] [Abstract][Full Text] [Related]
17. Cellulose derivatives as effective recrystallization inhibitor for ternary ritonavir solid dispersions: In vitro-in vivo evaluation.
Guan Q; Ma Q; Zhao Y; Jiang X; Zhang H; Liu M; Wang Z; Han J
Carbohydr Polym; 2021 Dec; 273():118562. PubMed ID: 34560973
[TBL] [Abstract][Full Text] [Related]
18. Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin.
Wei Y; Zhou S; Hao T; Zhang J; Gao Y; Qian S
Eur J Pharm Sci; 2019 Mar; 129():21-30. PubMed ID: 30590119
[TBL] [Abstract][Full Text] [Related]
19. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.
Kushida I; Gotoda M
Drug Dev Ind Pharm; 2013 Oct; 39(10):1582-8. PubMed ID: 22519663
[TBL] [Abstract][Full Text] [Related]
20. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
